Aclaris Therapeutics (ACRS) closed at $3.90 on November 6, 2026, up 8.0% from the previous close, on volume of 3,333,073 shares (30-day average 3,337,200).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Call with Delta Hedge | 20-Nov-26 4 C +23,800 Stock | 595 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Oppenheimer Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
TipRanks (Fri, 6-Nov 9:58 AM ET)
Aclaris Therapeutics (ACRS) Gets a Buy from Canaccord Genuity
TipRanks (Fri, 6-Nov 9:53 AM ET)
Aclaris Therapeutics GAAP EPS of -$0.12 beats by $0.04, revenue of $1.48M beats by $0.25M
Seeking Alpha News (Thu, 5-Nov 7:22 AM ET)
Globe Newswire (Thu, 5-Nov 6:59 AM ET)
Globe Newswire (Tue, 27-Oct 6:43 AM ET)
Globe Newswire (Tue, 27-Oct 6:00 AM ET)
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Aclaris Therapeutics Joins NASDAQ Biotechnology Index: What Inclusion Means for Investors
Market Chameleon (Mon, 22-Dec 5:50 AM ET)
Market Chameleon (Thu, 6-Nov 6:20 AM ET)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.
As of November 6, 2026, ACRS stock price climbed to $3.90 with 3,333,073 million shares trading.
ACRS has a beta of 0.84, meaning it tends to be less sensitive to market movements. ACRS has a correlation of 0.01 to the broad based SPY ETF.
ACRS has a market cap of $604.44 million. This is considered a Small Cap stock.
Last quarter Aclaris Therapeutics reported $1 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $244,712 and exceeded earnings estimates by $.04.
In the last 3 years, ACRS traded as high as $6.60 and as low as $.59.
The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, XPH, VTWO.
ACRS has outperformed the market in the last year with a price return of +71.8% while the SPY ETF gained +10.8%. However, in the short term, ACRS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -36.0% vs -4.1% return in SPY. But in the last 2 weeks, ACRS shares have fared better than the market returning +4.0% compared to SPY -3.2%.
ACRS support price is $3.42 and resistance is $3.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.
